AU4331400A - Neurotrophic substituted pyrimidines - Google Patents
Neurotrophic substituted pyrimidinesInfo
- Publication number
- AU4331400A AU4331400A AU43314/00A AU4331400A AU4331400A AU 4331400 A AU4331400 A AU 4331400A AU 43314/00 A AU43314/00 A AU 43314/00A AU 4331400 A AU4331400 A AU 4331400A AU 4331400 A AU4331400 A AU 4331400A
- Authority
- AU
- Australia
- Prior art keywords
- substituted pyrimidines
- neurotrophic
- neurodegenerative
- therapy
- contain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09288495 | 1999-04-08 | ||
| US09/288,495 US6583148B1 (en) | 1999-04-08 | 1999-04-08 | Neurotrophic substituted pyrimidines |
| PCT/US2000/009108 WO2000061562A1 (en) | 1999-04-08 | 2000-04-06 | Neurotrophic substituted pyrimidines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU4331400A true AU4331400A (en) | 2000-11-14 |
Family
ID=23107364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU43314/00A Abandoned AU4331400A (en) | 1999-04-08 | 2000-04-06 | Neurotrophic substituted pyrimidines |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6583148B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1165523B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4743463B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE377592T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU4331400A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2368843C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60037013T2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000061562A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5154728B2 (ja) * | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ,インコーポレイテッド | 神経栄養活性を有する置換5−アルキニルピリミジン |
| CN1324015C (zh) | 2002-02-13 | 2007-07-04 | 霍夫曼-拉罗奇有限公司 | 吡啶-和嘧啶-衍生物 |
| JP2005232081A (ja) * | 2004-02-19 | 2005-09-02 | Bayer Cropscience Ag | ベンジルピリミジン誘導体の農園芸用殺菌剤としての利用 |
| PT1725540E (pt) | 2004-03-05 | 2012-11-29 | Hoffmann La Roche | Diaminopirimidinas como antagonistas de p2x3 e p2x2/3 |
| US20110230479A1 (en) * | 2005-04-15 | 2011-09-22 | Longo Frank M | Neurotrophin mimetics and uses thereof |
| WO2006113097A2 (en) * | 2005-04-15 | 2006-10-26 | The University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
| EP2581440B1 (en) * | 2005-06-08 | 2016-03-16 | The University of North Carolina At Chapel Hill | Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics |
| ES2562056T3 (es) | 2005-09-01 | 2016-03-02 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores P2X3 y P2X2/3 |
| SI1924264T1 (sl) * | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot modulatorji p2x3 in p2x2/3 |
| ES2612890T3 (es) * | 2005-09-01 | 2017-05-19 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores de P2X3 y P2X2/3 |
| AU2006286576B2 (en) * | 2005-09-01 | 2012-06-14 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as P2X3 and P3X2/3 modulators |
| WO2007125952A1 (ja) * | 2006-04-28 | 2007-11-08 | Shionogi & Co., Ltd. | Npy y5受容体拮抗作用を有するアミン誘導体 |
| RU2433119C2 (ru) * | 2006-04-28 | 2011-11-10 | Шионоги Энд Ко., Лтд. | Производное амина, обладающее антагонистической активностью в отношении рецептора npy y5 |
| CN101479238B (zh) * | 2006-04-28 | 2013-08-21 | 盐野义制药株式会社 | 具有npyy5受体拮抗活性的胺衍生物 |
| SA08290668B1 (ar) | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها |
| US8227618B2 (en) | 2009-04-23 | 2012-07-24 | Shionogi & Co., Ltd. | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
| WO2011060262A1 (en) | 2009-11-12 | 2011-05-19 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| ES2691745T3 (es) * | 2011-04-08 | 2018-11-28 | Janssen Sciences Ireland Uc | Derivados de pirimidina para el tratamiento de infecciones víricas |
| DK2776439T3 (en) | 2011-11-09 | 2018-10-22 | Janssen Sciences Ireland Uc | PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
| DK2872515T3 (en) | 2012-07-13 | 2016-09-19 | Janssen Sciences Ireland Uc | MACROCYCLIC PURINES FOR TREATING VIRUS INFECTIONS |
| JP6302906B2 (ja) * | 2012-08-10 | 2018-03-28 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染および他の疾患を治療するためのアルキルピリミジン誘導体 |
| MX386924B (es) | 2012-10-10 | 2025-03-19 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades. |
| US9663474B2 (en) | 2012-11-16 | 2017-05-30 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections |
| KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
| US9828330B2 (en) | 2013-03-15 | 2017-11-28 | Pharmatrophix, Inc. | Non-peptide BDNF neurotrophin mimetics |
| CA2901839A1 (en) | 2013-03-15 | 2014-09-18 | Pharmatrophix, Inc. | Non-peptide bdnf neurotrophin mimetics |
| WO2014154859A1 (en) | 2013-03-29 | 2014-10-02 | Janssen R&D Ireland | Macrocyclic deaza-purinones for the treatment of viral infections |
| UA117586C2 (uk) | 2013-05-24 | 2018-08-27 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні піридину для лікування вірусних інфекцій та інших захворювань |
| MX392130B (es) | 2013-06-27 | 2025-03-21 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades. |
| ES2836881T3 (es) | 2013-07-30 | 2021-06-28 | Janssen Sciences Ireland Unlimited Co | Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales |
| MA45539A (fr) | 2016-07-01 | 2019-05-08 | Janssen Sciences Ireland Unlimited Co | Dihydropyranopyrimidines pour le traitement d'infections virales |
| SG10202010317VA (en) | 2016-09-29 | 2020-11-27 | Janssen Sciences Ireland Unlimited Co | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
| TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
| TWI815954B (zh) | 2018-08-27 | 2023-09-21 | 日商住友製藥股份有限公司 | 光學活性氮雜雙環衍生物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691655A (en) | 1952-05-24 | 1954-10-12 | Burroughs Wellcome Co | 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same |
| GB951431A (en) | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
| US3862190A (en) | 1972-09-08 | 1975-01-21 | Pfizer | 5-(unsubstituted and substituted phenoxy)-4-amino pyrimidines |
| DK397574A (cg-RX-API-DMAC7.html) * | 1973-08-24 | 1975-04-28 | Ciba Geigy Ag | |
| GB1523274A (en) | 1974-08-05 | 1978-08-31 | Ici Ltd | Herbicidal compositions containing substituted pyrimidine |
| FR2358148A1 (fr) | 1976-07-12 | 1978-02-10 | Dick Pr | Derives de 2,4-diaminopyrimidines et leur mise en solution en association avec des sulfamides |
| FR2397407A2 (fr) | 1977-07-11 | 1979-02-09 | Dick Pierre | Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides |
| FI895821A7 (fi) | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| IE912114A1 (en) | 1990-07-02 | 1992-01-15 | Union Pharma Scient Appl | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present |
| US5075305A (en) | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
| DE69201559T2 (de) | 1991-04-17 | 1995-07-13 | Pfizer | Pyrimidinderivate zur erhöhung der antitumoraktivität. |
| US5336677A (en) | 1991-10-24 | 1994-08-09 | American Home Products Corporation | Substituted aminopyrimidines as antihypertensives |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| EP0674627A1 (en) | 1992-12-18 | 1995-10-04 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
| EP0640599B1 (en) | 1993-08-26 | 1998-03-04 | Ono Pharmaceutical Co., Ltd. | 4-Aminopyrimidine derivatives |
| JPH08283246A (ja) | 1994-06-01 | 1996-10-29 | Nippon Soda Co Ltd | ピリミジン誘導体、その製造方法及び有害生物防除剤 |
| EP0826674A4 (en) | 1995-04-03 | 1998-07-08 | Sumitomo Pharma | EFFECTIVE PYRIMIDINE DERIVATIVES AS PSYCHOTROPE, AND METHOD FOR THE PRODUCTION THEREOF |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
-
1999
- 1999-04-08 US US09/288,495 patent/US6583148B1/en not_active Expired - Fee Related
-
2000
- 2000-04-06 AT AT00923138T patent/ATE377592T1/de not_active IP Right Cessation
- 2000-04-06 AU AU43314/00A patent/AU4331400A/en not_active Abandoned
- 2000-04-06 CA CA002368843A patent/CA2368843C/en not_active Expired - Fee Related
- 2000-04-06 WO PCT/US2000/009108 patent/WO2000061562A1/en not_active Ceased
- 2000-04-06 JP JP2000610837A patent/JP4743463B2/ja not_active Expired - Fee Related
- 2000-04-06 US US09/958,511 patent/US6916820B1/en not_active Expired - Fee Related
- 2000-04-06 EP EP00923138A patent/EP1165523B1/en not_active Expired - Lifetime
- 2000-04-06 DE DE60037013T patent/DE60037013T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002541245A (ja) | 2002-12-03 |
| DE60037013D1 (de) | 2007-12-20 |
| JP4743463B2 (ja) | 2011-08-10 |
| WO2000061562A1 (en) | 2000-10-19 |
| EP1165523B1 (en) | 2007-11-07 |
| US6583148B1 (en) | 2003-06-24 |
| CA2368843C (en) | 2009-10-20 |
| US6916820B1 (en) | 2005-07-12 |
| DE60037013T2 (de) | 2008-08-21 |
| EP1165523A1 (en) | 2002-01-02 |
| CA2368843A1 (en) | 2000-10-19 |
| ATE377592T1 (de) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2368843A1 (en) | Neurotrophic substituted pyrimidines | |
| AU2001273574A1 (en) | Substituted 5-alkynyl pyrimidines having neurotrophic activity | |
| AU9693998A (en) | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system | |
| WO2003092580A3 (en) | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | |
| AU2002327378A1 (en) | Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation | |
| WO2004014953A3 (en) | Anti-myelin associated glycoprotein (mag) antibodies | |
| TW200500344A (en) | Novel compounds | |
| IL111365A (en) | (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans their preparation and pharmaceutical compositions containing them | |
| GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
| MY118283A (en) | 6-phenyl-pyridin-2-ylamine derivatives | |
| GB0111186D0 (en) | Novel compounds | |
| AU2001266152A1 (en) | Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them | |
| MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
| MY124786A (en) | Bis-arylsulfones | |
| EP1032556A4 (en) | PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION | |
| BG103687A (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system | |
| MX2007006754A (es) | Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos. | |
| AU4910500A (en) | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | |
| MXPA02003484A (es) | Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba. | |
| IL143382A0 (en) | Human adult astrocytes, their preparation and uses thereof | |
| IL130586A0 (en) | IL6RIL6 chimera for the treatment of demyelinating diseases | |
| AU6428294A (en) | Imidazoloquinoxalinone derivatives as eaa antagonists | |
| AU2392797A (en) | Use of benzonaphthalene derivatives for the manufacture of medicaments for the treatment of diseases of the nervous system | |
| WO2001082954A3 (en) | Ceruloplasmin and uses thereof in neurodegenerative related conditions | |
| WO2000057862A3 (en) | Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |